Alpha Cognition Inc (ACOG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alpha Cognition Inc (ACOG) has a cash flow conversion efficiency ratio of -0.158x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.35 Million) by net assets ($33.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ACOG defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Alpha Cognition Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Alpha Cognition Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alpha Cognition Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alpha Cognition Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Waterco Ltd
AU:WAT
|
0.044x |
|
Jalles Machado S/A
SA:JALL3
|
0.104x |
|
Paxman AB
ST:PAX
|
-0.014x |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
0.020x |
|
Humanica Public Company Limited
BK:HUMAN
|
0.044x |
|
Siam Wellness Group Public Company Limited
BK:SPA
|
0.119x |
|
Energy World Corporation Ltd
AU:EWC
|
-0.017x |
|
SciVision Biotech Inc
TW:1786
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Alpha Cognition Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of Alpha Cognition Inc from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Alpha Cognition Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $41.46 Million | $-7.76 Million | -0.187x | -110.10% |
| 2023-12-31 | $-4.71 Million | $-8.73 Million | 1.852x | -73.54% |
| 2022-12-31 | $-1.32 Million | $-9.24 Million | 7.000x | +739.82% |
| 2021-12-31 | $9.03 Million | $-9.88 Million | -1.094x | +99.68% |
| 2020-12-31 | $16.01K | $-5.44 Million | -339.684x | -- |
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatm… Read more